MediBeacon is a medical technology company specializing in the advances of fluorescent tracer agents and transdermal measurement. The science is complex, but the outcomes are simple to understand. How it works >>
The MediBeacon Transdermal GFR Measurement System (TGFR) is engineered to allow non-invasive detection of the change in patient levels of a fluorescent GFR tracer agent over time via a sensor placed on the patient’s skin. The rate of decrease in the emitted fluorescence from Lumitrace® is automatically calculated and displayed on the monitor and is intended to provide information regarding the rate of clearance of Lumitrace injection which may be useful in the understanding of kidney function in real-time. The TGFR Monitor displays this information in the form of a transdermal GFR (tGFR).
The MediBeacon Transdermal GFR Measurement System (TGFR) is being studied across a range of GFR levels.
The MediBeacon TGFR proposed indications for use include the measurement of Glomerular Filtration Rate (GFR) in patients with impaired or normal renal function. The FDA granted the TGFR a Breakthrough Device Designation because better tools are needed for the management of kidney patients. Subsequent to an eventual regulatory approval any improvement in the standard of care would need to be demonstrated in the clinic.